000141819 001__ 141819
000141819 005__ 20240229112527.0
000141819 0247_ $$2doi$$a10.1007/s00262-018-2279-9
000141819 0247_ $$2pmid$$apmid:30478475
000141819 0247_ $$2ISSN$$a0340-7004
000141819 0247_ $$2ISSN$$a1432-0851
000141819 0247_ $$2ISSN$$a=
000141819 0247_ $$2ISSN$$aCancer
000141819 0247_ $$2ISSN$$aimmunology,
000141819 0247_ $$2ISSN$$aimmunotherapy
000141819 0247_ $$2ISSN$$a(Internet)
000141819 037__ $$aDKFZ-2018-02087
000141819 041__ $$aeng
000141819 082__ $$a610
000141819 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000141819 245__ $$aCan benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?315
000141819 260__ $$aHeidelberg$$bSpringer$$c2019
000141819 3367_ $$2DRIVER$$aarticle
000141819 3367_ $$2DataCite$$aOutput Types/Journal article
000141819 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1558077500_10927
000141819 3367_ $$2BibTeX$$aARTICLE
000141819 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141819 3367_ $$00$$2EndNote$$aJournal Article
000141819 520__ $$aAn association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of 18F-FDG PET/CT lymphoid tissue changes in the mediastinal/hilar lymph nodes and the spleen in response to ipilimumab administration in metastatic melanoma.A total of 41 patients with unresectable metastatic melanoma underwent 18F-FDG PET/CT before the start of ipilimumab (baseline PET/CT), after two cycles (interim PET/CT) and at the end of treatment (late PET/CT). Data analysis was focused on the mediastinal/hilar lymph nodes and the spleen. The patients' best clinical response (BCR) was used as reference.According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a 'sarcoid-like lymphadenopathy' as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative 18F-FDG PET spleen-related parameters at baseline and as response to treatment were detected.Based on our findings, 10% patients in the interim or late PET/CT showed 'sarcoid-like lymphadenopathy' as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative 18F-FDG PET analysis of the spleen showed a poor performance in predicting clinical benefit to ipilimumab.
000141819 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000141819 588__ $$aDataset connected to CrossRef, PubMed,
000141819 7001_ $$0P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aLarribère, Lionel$$b1$$udkfz
000141819 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b2$$udkfz
000141819 7001_ $$0P:(DE-HGF)0$$aHassel, Jessica C$$b3
000141819 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b4$$eLast author$$udkfz
000141819 773__ $$0PERI:(DE-600)1458489-x$$a10.1007/s00262-018-2279-9$$n2$$p297-303$$tCancer immunology immunotherapy$$v68$$x1432-0851$$y2019
000141819 909CO $$ooai:inrepo02.dkfz.de:141819$$pVDB
000141819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141819 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141819 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000141819 9141_ $$y2019
000141819 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141819 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER IMMUNOL IMMUN : 2017
000141819 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141819 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141819 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141819 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141819 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141819 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141819 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141819 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141819 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141819 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141819 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141819 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141819 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000141819 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x1
000141819 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000141819 980__ $$ajournal
000141819 980__ $$aVDB
000141819 980__ $$aI:(DE-He78)E060-20160331
000141819 980__ $$aI:(DE-He78)A370-20160331
000141819 980__ $$aI:(DE-He78)C060-20160331
000141819 980__ $$aUNRESTRICTED